MRKR has been the subject of several other research reports. Zacks Investment Research downgraded TapImmune from a buy rating to a hold rating in a research report on Wednesday, July 17th. Nomura reiterated a buy rating and issued a $16.00 price objective on shares of TapImmune in a research report on Tuesday, August 13th. Janney Montgomery Scott reiterated a buy rating on shares of TapImmune in a research report on Sunday, July 21st. Oppenheimer assumed coverage on TapImmune in a research report on Wednesday, July 3rd. They issued an outperform rating and a $15.00 price objective for the company. Finally, Roth Capital assumed coverage on TapImmune in a research report on Thursday, May 30th. They issued a buy rating and a $10.00 price objective for the company. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. TapImmune has an average rating of Buy and an average price target of $10.21.
Shares of MRKR stock opened at $5.03 on Wednesday. The company has a current ratio of 16.85, a quick ratio of 16.85 and a debt-to-equity ratio of 0.01. TapImmune has a fifty-two week low of $3.97 and a fifty-two week high of $10.60. The stock has a 50 day moving average price of $6.08 and a two-hundred day moving average price of $5.98.
In other TapImmune news, insider Peter L. Hoang bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The stock was bought at an average price of $4.62 per share, for a total transaction of $46,200.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 23.70% of the stock is owned by corporate insiders.
An institutional investor recently raised its position in TapImmune stock. Riggs Asset Managment Co. Inc. raised its stake in TapImmune Inc. (NASDAQ:MRKR) by 68.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,919 shares of the company’s stock after acquiring an additional 18,650 shares during the period. Riggs Asset Managment Co. Inc. owned approximately 0.10% of TapImmune worth $303,000 as of its most recent SEC filing. Institutional investors own 37.31% of the company’s stock.
TapImmune Company Profile
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Featured Article: What is Considered a Good Return on Equity (ROE)?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.